CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis

Journal of Immune Based Therapies and Vaccines

Volumn 8, Issue , 2010, Pages

  Bhagawati Prasad, Vijay N S ^a   De Leenheer, Evy ^a   Keefe, Nadine P ^a   Ryan, Lorna A ^a   Carlring, Jennifer ^a   Heath, Andrew W ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Sheffield Bioincubator ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD40; OVALBUMIN; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPROPHYLAXIS; INCUBATION TIME; MOUSE; NONHUMAN;

EID: 77349090240     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-8-1     Document Type: Article

References (22)

1. Ertl HC. Novel vaccines to human rabies. PLoS Negl Trop Dis 2009, 3:e515. 10.1371/journal.pntd.0000515, 2742899, 19787033.
2. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002, 287:2236-2252. 10.1001/jama.287.17.2236, 11980524.
3. Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C, Orlin S, Levenson R. Postexposure effectiveness of varicella vaccine. Pediatrics 2000, 105:84-88. 10.1542/peds.105.1.84, 10617709.
4. Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J 1998, 17:256-257. 10.1097/00006454-199803000-00020, 9535260.
5. Kohl I, Nemecek V, Summerová M, Chlíbek R, Nad'ová K, Mináriková O. Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks. Eur J Epidemiol 2006, 21:893-899. 10.1007/s10654-006-9081-2, 17160428.
6. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008, 4:347-349.
7. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, Greenacre M. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. 10.1016/S0140-6736(09)61248-4, 19586656.
8. Barr TA, Carlring J, Heath AW. Co-stimulatory agonists as immunological adjuvants. Vaccine 2006, 24:3399-3407. 10.1016/j.vaccine.2006.02.022, 16530301.
9. De Gregorio E, D'Oro U, Wack A. Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 2009, 21:339-345. 10.1016/j.coi.2009.05.003, 19493664.
10. Mesa C, de Leon J, Fernandez LE. Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 2006, 24:2692-2699. 10.1016/j.vaccine.2005.08.111, 16316710.
11. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007, 6:797-808. 10.1586/14760584.6.5.797, 17931159.
12. Hatzifoti C, Bacon A, Marriott H, Laing P, Heath AW. Liposomal co-entrapment of CD40mAb induces enhanced IgG responses against bacterial polysaccharide and protein. PLoS ONE 2008, 3:e2368. 10.1371/journal.pone.0002368, 2387064, 18523585.
13. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, Vasilakos JP, Noelle RJ, Kedl RM. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004, 199:775-784. 10.1084/jem.20031591, 2212721, 15007094.
14. Heath AW, Chang R, Harada N, Santos-Argumedo L, Gordon J, Hannum C, Campbell D, Shanafelt AB, Clark EA, Torres R, et al. Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. Cell Immunol 1993, 152:468-480. 10.1006/cimm.1993.1305, 7504979.
15. Dullforce P, Sutton DC, Heath AW. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat Med 1998, 4:88-91. 10.1038/nm0198-088, 9427612.
16. Barr TA, McCormick AL, Carlring J, Heath AW. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology 2003, 109:87-92. 10.1046/j.1365-2567.2003.01634.x, 1782935, 12709021.
17. Hatzifoti C, Heath AW. CD40-mediated enhancement of immune responses against three forms of influenza vaccine. Immunology 2007, 122:98-106. 10.1111/j.1365-2567.2007.02617.x, 2265986, 17472718.
18. Carlring J, Barr TA, McCormick AL, Heath AW. CD40 antibody as an adjuvant induces enhanced T cell responses. Vaccine 2004, 22:3323-3328. 10.1016/j.vaccine.2004.02.043, 15308355.
19. Tang Y, Akbulut H, Maynard J, Petersen L, Fang X, Zhang WW, Xia X, Koziol J, Linton PJ, Deisseroth A. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer. J Immunol 2006, 177:5697-5707.
20. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007, 13:1083-1088. 10.1158/1078-0432.CCR-06-1893, 17317815.
21. Barr TA, Carlring J, Heath AW. CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens. Vaccine 2005, 23:3477-3482. 10.1016/j.vaccine.2004.12.025, 15837371.
22. Barr TA, Heath AW. Functional activity of CD40 antibodies correlates to the position of binding relative to CD154. Immunology 2001, 102:39-43. 10.1046/j.1365-2567.2001.01148.x, 1783151, 11168635.